Companies:
50,244
Total Market Cap:
139210354677174.03
Global Rank
#49717
Country Rank
#6502
Market Cap
5,332
Price
0.0001
Change (%)
9900.00%
Volume
30,065
Aridis Pharmaceuticals's latest marketcap:
5,332
As of 08/02/2025, Aridis Pharmaceuticals's market capitalization has reached $5,332. According to our data, Aridis Pharmaceuticals is the 49717th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 5,332 |
| Revenue (ttm) | 22.36 M |
| Net Income (ttm) | -1,142,000 |
| Shares Out | 53.32 M |
| EPS (ttm) | -0.04 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 04/25/2025 |
Market Cap Chart
Data Updated: 08/02/2025
Aridis Pharmaceuticals's yearly market capitalization.
Aridis Pharmaceuticals has seen its market value drop from $89.88 M to $5,332 since 2018, representing a total decrease of 99.99% and an annual compound decline rate (CAGR) of 77.16%.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 08/02/2025 | $5,332 | -99.01% | 49717 |
| 12/31/2024 | $5,332 | -99.83% | 48414 |
| 12/29/2023 | $3.18 M | -89.17% | 46739 |
| 12/30/2022 | $29.39 M | -10.24% | 44997 |
| 12/31/2021 | $32.75 M | -46.41% | 42962 |
| 12/31/2020 | $61.1 M | 54.06% | 39726 |
| 12/31/2019 | $39.66 M | -55.88% | 37013 |
| 12/31/2018 | $89.88 M | 35613 |
Company Profile
Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on discovering and developing targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening infections.
Key Product Candidates
- AR-301: A fully human IgG1 monoclonal antibody that has completed Phase III pivotal trials for lung infections caused by S. aureus alpha-toxin. It is also being developed as an adjunctive therapy with standard-of-care antibiotics for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).
- AR-320: A fully human IgG1 mAb targeting S. aureus alpha-toxin to treat infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible S. aureus (MSSA).
- AR-501: An inhaled gallium citrate in Phase 1/2a trials for chronic lung infections associated with cystic fibrosis.
- AR-101: A human IgM mAb in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11.
Preclinical Programs
- AR-401: Targets infections caused by Acinetobacter baumannii.
- AR-201: A fully human IgG1 mAb for respiratory syncytial virus (RSV).
- AR-701: A cocktail of two fully human immunoglobulin 1 antibodies.
Founded in 2003, Aridis Pharmaceuticals is headquartered in Los Gatos, California.
Frequently Asked Questions
-
What is Aridis Pharmaceuticals's (OTC-ARDS) current market cap?As of 08/02/2025, Aridis Pharmaceuticals (including the parent company, if applicable) has an estimated market capitalization of $5,332 USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Aridis Pharmaceuticals (OTC-ARDS) rank globally by market cap?Aridis Pharmaceuticals global market capitalization ranking is approximately 49717 as of 08/02/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.